Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 290–300 (2005)Cite this article

Abstract

Cyclo-oxygenase (COX) 1 mediates the production of thromboxane A2 in platelets, leading to platelet aggregation and vasoconstriction. Conversely, COX2 catalyzes endothelial prostacyclin synthesis, which effectively counteracts thromboxane A2, triggering vasodilation and platelet inhibition. Selective COX2 inhibitors decrease prostacyclin production, potentially disrupting homeostasis and creating a prothrombotic state. The VIGOR study findings of increased cardiovascular risk with rofecoxib were subsequently confirmed by large meta-analyses, observational studies and recent APPROVe trial publication. The APC trial findings of increased cardiovascular risk with Celebrex® (celecoxib) conflict with those in the ADAPT trial, the upcoming PreSAP publication, a case-control study by Graham et al. and prior large clinical trials, meta-analyses and observational studies of this drug. Therefore, while an adverse class effect is a possibility for COX2 inhibitors, the published data are inconsistent. Baseline cardiovascular risk in patients might contribute significantly to these findings. In light of the negative Vioxx® (rofecoxib) publicity, however, COX2 inhibitors might forever remain underinvestigated. The relative selectivity of these compounds for COX2 is extremely variable, casting significant doubt on the class-effect hypothesis. Improved endothelial function has also been reported with celecoxib, leading to endothelium-dependent vasodilation, and associated decreases in C-reactive protein and LDL cholesterol. The addition of meloxicam to low-dose aspirin and heparin has improved clinical outcomes after acute coronary syndromes. These are the first studies suggesting improvement in endothelial function and reduction of inflammation with COX2 inhibition. Thus, more randomized controlled trials are needed to study the relative cardiovascular effects of different COX2 inhibitors, alone and in combination with aspirin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Cyclo-oxygenase 2 inhibitors and prostacyclin–thromboxane-A2 homeostasis.

Similar content being viewed by others

References

  1. Sanmuganathan PS et al. (2001) Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85: 265–271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. US Preventive Services Task Force (2002) Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 136: 157–160

  3. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81–106

  4. Ryan TJ et al. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 34: 890–911

    Article  CAS  PubMed  Google Scholar 

  5. Brooks PM and Day RO (1991) Nonsteroidal anti-inflammatory drugs—differences and similarities. N Engl J Med 324: 1716–1725

    Article  CAS  PubMed  Google Scholar 

  6. IMS Health Inc. (online 26 April 2002) IMS reports 16.9 percent growth in 2001 U.S. prescription sales.(Accessed 22 April 2005)

  7. Vane JR and Botting RM (1998) Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 104 (Suppl 3A): 2S–8S

    Article  CAS  PubMed  Google Scholar 

  8. Kam PC and See AU (2000) Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 55: 442–449

    Article  CAS  PubMed  Google Scholar 

  9. Whittle BJ et al. (1980) Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284: 271–273

    Article  CAS  PubMed  Google Scholar 

  10. Cryer B and Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413–421

    Article  CAS  PubMed  Google Scholar 

  11. Reilly IA and Fitzgerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 69: 180–186

    CAS  PubMed  Google Scholar 

  12. Patrono C et al. (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 1177–1184

    Article  CAS  PubMed  Google Scholar 

  13. FitzGerald GA (2002) Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89: 26D–32D

    Article  CAS  PubMed  Google Scholar 

  14. Catella-Lawson F and Crofford LJ (2001) Cyclooxygenase inhibition and thrombogenicity. Am J Med 110 (Suppl 3A): 28S–32S

    Article  CAS  PubMed  Google Scholar 

  15. Mukherjee D (2002) Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 63: 817–821

    Article  CAS  PubMed  Google Scholar 

  16. Linton MF and Fazio S (2004) Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 4: 116–123

    Article  CAS  PubMed  Google Scholar 

  17. Weir MR et al. (2003) Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146: 591–604

    Article  CAS  PubMed  Google Scholar 

  18. Meagher EA et al. (2003) Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. Drug Saf 26: 913–924

    Article  CAS  PubMed  Google Scholar 

  19. McAdam BF et al. (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96: 272–277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yamamoto T et al. (2001) Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. Pharmacology 63: 28–33

    Article  CAS  PubMed  Google Scholar 

  21. Bing RJ and Lomnicka M (2002) Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 39: 521–522

    Article  CAS  PubMed  Google Scholar 

  22. Aw TJ et al. (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165: 490–496

    Article  CAS  PubMed  Google Scholar 

  23. Topper JN et al. (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93: 10417–10422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Shinmura K et al. (2000) Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197–10202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bolli R et al. (2002) Discovery of a new function of cyclooxygenase (COX)-2: Cox-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506–519

    Article  CAS  PubMed  Google Scholar 

  26. Hennan JK et al. (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104: 820–825

    Article  CAS  PubMed  Google Scholar 

  27. Dowd NP et al. (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108: 585–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Cheng Y et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539–541

    Article  CAS  PubMed  Google Scholar 

  29. Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1528

    Article  CAS  PubMed  Google Scholar 

  30. Solomon DH et al. (2002) Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162: 1099–1104

    Article  CAS  PubMed  Google Scholar 

  31. Watson DJ et al. (2002) Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162: 1105–1110

    Article  CAS  PubMed  Google Scholar 

  32. Rahme E et al. (2002) Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162: 1111–1115

    Article  CAS  PubMed  Google Scholar 

  33. Ray WA et al. (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359: 118–123

    Article  CAS  PubMed  Google Scholar 

  34. Graham DJ et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475–481

    Article  CAS  PubMed  Google Scholar 

  35. Silverstein FE et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247–1255

    Article  CAS  PubMed  Google Scholar 

  36. Catella-Lawson F et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–1817

    Article  CAS  PubMed  Google Scholar 

  37. Nussmeier NA et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091

    Article  CAS  PubMed  Google Scholar 

  38. Whelton A (online 7 March 2005) Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery [http://www.acc05online.acc.org/highlights/keyLectures.aspx?sessionId=8030&date=7] (accessed 22 April 2005)

  39. Matsumoto AK et al. (2002) A randomized controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 29: 1623–1630

    CAS  PubMed  Google Scholar 

  40. Farkouh ME et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675–684

    Article  CAS  PubMed  Google Scholar 

  41. Mukherjee D et al. (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959

    Article  CAS  PubMed  Google Scholar 

  42. Reicin AS et al. (2002) Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflamamtory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 89: 204–209

    Article  CAS  PubMed  Google Scholar 

  43. Konstam MA et al. (2001) Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation 104: 2280–2288

    Article  CAS  PubMed  Google Scholar 

  44. White WB et al. (2003) Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 92: 411–418

    Article  CAS  PubMed  Google Scholar 

  45. White WB et al. (2004) Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 11: 244–250

    Article  PubMed  Google Scholar 

  46. Mamdani M et al. (2003) Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 163: 481–486

    Article  CAS  PubMed  Google Scholar 

  47. Solomon DH et al. (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–2073

    Article  CAS  PubMed  Google Scholar 

  48. Shaya FT et al. (2005) Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 165: 181–186

    Article  CAS  PubMed  Google Scholar 

  49. Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. N Engl J Med 352: 1092–1102

    Article  CAS  PubMed  Google Scholar 

  50. Solomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. Ademona Prevention with Celecoxib (APC) Study Investigators. N Engl J Med 352: 1071–1080

    Article  CAS  PubMed  Google Scholar 

  51. Levin B (Online 18 April 2005) The PreSAP Trial (Prevention of Colorectal Sporadic Adenomatous Polyps). [http://www.masterdocs.com/PDF/C7%20The%20PreSAP%20Trial%20(Prevention%20of%20Colorectal%20Sporadic%20Adenomatous%20Polyps)%20-%20Bernard%20Levin%20MD.pdf] (accessed 22 April 2005)

  52. NIH Department of Health and Human Services, NIH News (online 20 December 2004) Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial [http://www.nih.gov/news/pr/dec2004/od-20.htm] (accessed 22 April 2005)

  53. Konstam MA and Weir MR (2002) Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med 69 (Suppl 1): S147–S152

    Google Scholar 

  54. Altman R et al. (2002) Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 106: 191–195

    Article  CAS  PubMed  Google Scholar 

  55. Chenevard R et al. (2003) Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405–409

    Article  PubMed  Google Scholar 

  56. Van Hecken A et al. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40: 1109–1120

    CAS  PubMed  Google Scholar 

  57. Dalen JE (2002) Selective COX-2 inhibitors, NSAIDs, aspirin and myocardial infarction. Arch Intern Med 162: 1091–1092

    Article  PubMed  Google Scholar 

  58. Jenkins JK (online 6 April 2005) Memorandum: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. (accessed 22 April 2005)

  59. Abramson SB et al. (2001) Controversies in COX-2 inhibitor therapy: closing remarks. Clin Exp Rheumatol 19 (Suppl 25): S77–S80

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. G Spektor is a Fellow in and V Fuster is the Director of the Zena and Michael A Wiener Cardiovascular Institute and The Marie-Josée and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, New York, NY, USA

    Gary Spektor & Valentin Fuster

Authors
  1. Gary Spektor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentin Fuster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valentin Fuster.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Glossary

ODDS RATIO (OR)

Ratio of odds of an event in intervention group to odds in control group; when <1 for an undesirable outcome, the intervention reduced the risk

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spektor, G., Fuster, V. Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?. Nat Rev Cardiol 2, 290–300 (2005). https://doi.org/10.1038/ncpcardio0214

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0214

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing